Teva elects Prof. Varda Shalev to Board effective Sep 1, 2023

TEVA PHARMACEUTICAL INDUSTRIES LTD

Prof. Varda Shalev elected as independent director, effective Sep 1, 2023, until 2024 annual meeting.
Shalev is a healthcare executive, managing partner at Team8 Health VC, and professor at Tel Aviv University.
No arrangements or material interests with other parties; compensation same as other non-executive directors.
No family relationships with any director or executive officer of Teva.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Prof. Varda Shalev

member of the Board

TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD

Effective: 2023-09-01
Filed: August 2, 2023, 7:59 PM ET

On August 1, 2023, at a meeting of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”), the Board elected Prof. Varda Shalev to serve as a member of the Board, effective September 1, 2023, until Teva’s 2024 annual meeting of shareholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Prof. Varda Shalev was elected as member of the Board at TEVA PHARMACEUTICAL INDUSTRIES LTD.

Action: elected
Role: member of the Board

Exact text from the filing

On August 1, 2023, at a meeting of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”), the Board elected Prof. Varda Shalev to serve as a member of the Board, effective September 1, 2023, until Teva’s 2024 annual meeting of shareholders.

View on SEC.gov

TEVA PHARMACEUTICAL INDUSTRIES LTD filing history →

Source: SEC EDGAR

accession 0001193125-23-201735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.